Scisparc Ltd (SPRC)
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on cannabinoid-based therapies. Its development pipeline includes SCI-110, which is being studied for Tourette syndrome, Alzheimer’s disease, and agitation; SCI-210, which is being developed for autism spectrum disorder and status epilepticus; and CannAmide, a product positioned for inflammation and chronic pain. In addition to its drug candidates, the company sells hemp seed oil-based and related products. SciSparc has partnered with Procaps on the development and commercial manufacture of SCI-110, palmitoylethanolamide oral tablets, and CannAmide softgel capsules. It also has an agreement with The Israeli Medical Center for Alzheimer’s to support a phase IIa trial of SCI-110 in Alzheimer’s disease and agitation, and a collaboration with Clearmind Medicine Inc. Founded in 2004 and headquartered in Tel Aviv-Yafo, Israel, the company was previously known as Therapix Biosciences Ltd. before adopting its current name in January 2021.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SPRC
|
$5.42
|
15.0% Upside
|
Fair
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
-0.2x
|
0.6x
|
3.2x
|
2.694 M
|
-614.159 K
|
9.2%
|
96.5%
|
-44.5
|
—
|
34.0%
|
